Article Details

BridgeBio's acoramidis fails to meet primary endpoint in Phase 3 ATTRibute-CM study - MarketWatch

Retrieved on: 2021-12-27 12:14:14

Tags for this article:

Click the tags to see associated articles and topics

BridgeBio's acoramidis fails to meet primary endpoint in Phase 3 ATTRibute-CM study - MarketWatch. View article details on hiswai:

Excerpt

The stock, which has been halted for news until 7:30 a.m. Eastern, has plunged 42.9% this year while the iShares Biotechnology ETF IBB, ...

Article found on: www.marketwatch.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up